D.E. Shaw & Co
TVTX icon

D.E. Shaw & Co’s Travere Therapeutics TVTX Stock Holding History

D.E. Shaw & Co’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-20,000
Closed -$421K – 3782
2017
Q4 		$421K Hold
20,000
– – ﹤0.01% 3081
2017
Q3 		$498K Hold
20,000
– – ﹤0.01% 2908
2017
Q2 		$388K Hold
20,000
– – ﹤0.01% 2924
2017
Q1 		$369K Sell
20,000
-40,000
-67% -$782K ﹤0.01% 2882
2016
Q4 		$1.14M Hold
60,000
– – ﹤0.01% 2383
2016
Q3 		$1.34M Hold
60,000
– – ﹤0.01% 2194
2016
Q2 		$1.07M Buy
60,000
+10,000
+20% +$162K ﹤0.01% 2376
2016
Q1 		$683K Buy
+50,000
New +$759K ﹤0.01% 2597

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co's TVTX Position: Q1 2026 in Review

D.E. Shaw & Co reduced its Travere Therapeutics (TVTX) stake by 24% in Q1 2026, selling an estimated $7.71M and leaving 836,544 shares worth $24.9M. The position accounts for 0.01% of the portfolio, ranked #1014.

D.E. Shaw & Co first reported a position in TVTX in Q1 2014 and has held it in 47 quarters since. The position peaked at $42.1M in Q4 2020. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • D.E. Shaw & Co held 836,544 shares of Travere Therapeutics worth $24.9M as of Q1 2026.
  • D.E. Shaw & Co sold 258,012 Travere Therapeutics shares in Q1 2026, an estimated $7.71M.
  • Travere Therapeutics made up 0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #1014 holding.
  • D.E. Shaw & Co first reported a position in Travere Therapeutics in Q1 2014 and has held it in 47 quarters since.
  • D.E. Shaw & Co's Travere Therapeutics position peaked at $42.1M in Q4 2020.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.